Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials

Patient demographics, disease characteristics, and treatment history can impact the efficacy of biologic treatments in patients with psoriasis. Understanding the efficacy of biologics, such as bimekizumab, across diverse patient subgroups is important for optimising treatment outcomes. Here, we assess whether high overall clinical responses observed in bimekizumab-treated patients with moderate to severe plaque psoriasis are consistent across subgroups, both versus comparators and with long-term treatment. Data were analysed post hoc from the BE SURE, BE VIVID, and BE READY phase 3 trials, their open-label extension (OLE) BE BRIGHT, and the BE RADIANT phase 3b trial. Patients received either bimekizumab or adalimumab to week 24 (BE SURE), bimekizumab or ustekinumab to week 52 (BE VIVID), and bimekizumab or secukinumab to week 48 (BE RADIANT). In the 3-year pooled analysis (all trials), included patients received bimekizumab continuously from baseline into the OLE. Subgroups of patients with moderate to severe plaque psoriasis were defined by age, sex, weight, disease duration, disease severity, nail involvement (modified Nail Psoriasis Severity Index > 0), and prior biologic exposure, at baseline. The proportions of patients achieving complete skin clearance (PASI 100; 100% improvement from baseline in Psoriasis Area and Severity Index) in each subgroup are reported alongside 95% confidence intervals (CI). Modified non-responder imputation (mNRI) was used for missing data. Following comparator-controlled periods, the proportion of bimekizumab-treated patients who achieved PASI 100 was consistent across subgroups and numerically greater versus patients who received adalimumab (to week 24), ustekinumab (to week 52), and secukinumab (to week 48) in all subgroups. Among patients who received bimekizumab continuously for 3 years (N = 1107), PASI 100 response rates remained consistent across age (68.6% [40 to < 65 years]–73.7% [≥ 65 years]), sex (69.6% [male]–71.4% [female]), weight (63.4% [≥ 103.9 kg]–75.5% [< 74.3 kg]), disease duration (65.5% [≤ 5 years]–71.1% [> 20 years]), disease severity (67.7% [PASI 12 to < 15]–71.1% [PASI ≥ 20]), nail involvement (69.1% [yes]/71.3% [no]), and prior biologic exposure (71.7% [yes]/69.1% [no]; prior anti-TNF exposure 67.6% [yes]/70.6% [no]) subgroups; 95% CIs overlapped in all instances, indicating no meaningful differences between subgroups. Bimekizumab demonstrated consistently high long-term efficacy in patients with psoriasis across diverse subgroups. Higher rates of PASI 100 were achieved with bimekizumab versus adalimumab, ustekinumab, and secukinumab, across all subgroups. These results highlight bimekizumab as an effective treatment for a broad range of people living with psoriasis. NCT03412747, NCT03370133, NCT03410992, NCT03598790, NCT03536884. Psoriasis is a long-lasting skin condition affecting around 1 in every 50 people. Since psoriasis is common, people with the condition differ in terms of who they are, how psoriasis affects them, other health conditions they may have, and past treatments. These differences can affect how a drug works and choosing the correct treatment for individual patients is important. Finding treatments that work equally well across diverse groups of people would help make treatment decisions easier. Previous studies have shown that bimekizumab, a treatment for psoriasis, works better than other treatments (adalimumab, ustekinumab, and secukinumab) to completely clear the skin and keep it clear for a long time. To see if these results were consistent across diverse groups of people, we categorised patients into subgroups based on age, sex, body weight, health conditions, psoriasis duration and severity, and prior treatments. We analysed results from people taking bimekizumab and other similar treatments for periods of up to 1 year, as well as those receiving bimekizumab continuously for 3 years. Bimekizumab consistently helped a high number of patients achieve completely clear skin, regardless of their background. In all subgroups, approximately 7 out of 10 patients had completely clear skin after 3 years of continuous bimekizumab treatment. Over periods of up to 1 year, more patients treated with bimekizumab had completely clear skin compared with adalimumab, ustekinumab, and secukinumab, in all analysed subgroups. These results indicate that bimekizumab is an effective treatment for a wide range of people with moderate to severe psoriasis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.